Development of a Patient-Oriented Organizational Management System for Intravitreal Injection Therapy in a Standardized “Treat-and-Extend” Regime at a University Eye Clinic

Abstract

Background The treatment of macular edema with intravitreal injections has revolutionized the treatment of associated diseases in ophthalmology. However, with a few exceptions, this is a chronic treatment where patients require many injections and usually need to stay in treatment for years. Patient adherence and control of patient flow are critical to treatment success. In this manuscript, we describe the development of a patient-oriented organization management for intravitreal injections in a university hospital.

Material and Methods In 2015, the intravitreal treatment in our clinic was switched to the treat-and-extend regime. At the same time, the optimization of the previous organizational processes in perioperative management was evaluated. For the period 2015 to 2018, we analyzed and gradually optimized the procedures of our intravitreal injection therapy in a survey with a specialized service provider.

Results Through the analysis of the original processes, the patient appointment was optimized, work processes were summarized, spatially reorganized and there was only a slight increase in the number of staff involved compared with the significant increase in the number of injections. Through these measures, the total in-hospital-time of the patients could be drastically reduced and at the same time the number of patients on one operation day could be multiplied.

Conclusion In the context of chronic treatment with intravitreal injections, the care of an increased number of patients is a logistical challenge. By optimizing processes, existing resources can be better used to meet the increased demands. An optimized system offers the patient greater adherence and a better visual outcome largely independent of the medication used.

Key words

anti-VEGF - macular edema - intravitreal injections - treat-and-extend - patient management - retina

Publication History

Received: 20 April 2020

Accepted: 13 August 2020

Article published online:
26 November 2020

• References/Literatur

• 1 Rosenfeld PJ, Brown DM, Heier JS. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431 doi:10.1056/NEJMoa054481
• 2 Brown DM, Kaiser PK, Michels M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444 doi:10.1056/NEJMoa062655
• 3 Massin P, Bandello F, Garweg JG. et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405 doi:10.2337/dc10-0493
• 4 Nguyen QD, Brown DM, Marcus DM. et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119: 789-801 doi:10.1016/j.ophtha.2011.12.039
• 5 Campochiaro PA, Brown DM, Awh CC. et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011; 118: 2041-2049 doi:10.1016/j.ophtha.2011.02.038
• 6 Brown DM, Campochiaro PA, Bhisitkul RB. et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011; 118: 1594-1602 doi:10.1016/j.ophtha.2011.02.022
• 7 Heier JS, Brown DM, Chong V. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-2548 doi:10.1016/j.ophtha.2012.09.006
• 8 Korobelnik JF, Do DV, Schmidt-Erfurth U. et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247-2254 doi:10.1016/j.ophtha.2014.05.006
• 9 Brown DM, Schmidt-Erfurth U, Do DV. et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 2015; 122: 2044-2052 doi:10.1016/j.ophtha.2015.06.017
• 10 Heier JS, Clark WL, Boyer DS. et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; 121: 1414-1420.e1 doi:10.1016/j.ophtha.2014.01.027
• 11 Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Maguire MG, Martin DF. et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: The comparison of age-related macular degeneration treatments trials. Ophthalmology 2016; 123: 1751-1761 doi:10.1016/j.ophtha.2016.03.045
• 12 Writing Committee for the Diabetic Retinopathy Clinical Research Network. Gross JG, Glassman AR. et al. Panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA 2015; 314: 2137-2146 doi:10.1001/jama.2015.15217
• 13 Finger RP, Wiedemann P, Blumhagen F. et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study – a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013; 91: 540-546 doi:10.1111/j.1755-3768.2012.02493.x
• 14 Ziemssen F, Eter N, Fauser S. et al. Retrospektive Untersuchung der Anti-VEGF-Behandlungsrealität und Wirksamkeit bei Patienten mit neovaskulärer altersabhängiger Makuladegeneration (nAMD) in Deutschland. Ophthalmologe 2015; 112: 246-254 doi:10.1007/s00347-014-3217-7
• 15 Holz FG, Tadayoni R, Beatty S. et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015; 99: 220-226 doi:10.1136/bjophthalmol-2014-305327
• 16 Framme C, Eter N, Hamacher T. et al. Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany. Ophthalmol Retin 2018; 2: 539-549 doi:10.1016/j.oret.2017.09.017
• 17 Stefanickova J, Cunha-Vaz J, Ulbig M. et al. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS). Acta Ophthalmol 2018; 96: e942 doi:10.1111/aos.13771
• 18 Ziemssen F, Wachtlin J, Kuehlewein L. et al. Intravitreal ranibizumab therapy for diabetic macular edema in routine practice: Two-year real-life data from a non-interventional, multicenter study in Germany. Diabetes Ther 2018; 9: 2271-2289 doi:10.1007/s13300-018-0513-2
• 19 Lala C, Framme C, Wolf-Schnurrbusch UEK. et al. Three-year results of visual outcome with disease activity-guided ranibizumab algorithm for the treatment of exudative age-related macular degeneration. Acta Ophthalmol 2013; 91: 526-530 doi:10.1111/j.1755-3768.2012.02457.x
• 20 Holekamp NM, Campbell J, Almony A. et al. Vision outcomes following anti-vascular endothelial growth factor treatment of diabetic macular edema in clinical practice. Am J Ophthalmol 2018; 191: 83-91 doi:10.1016/j.ajo.2018.04.010
• 21 Date RC, Shen KL, Shah BM. et al. Accuracy of detection and grading of diabetic retinopathy and diabetic macular edema using teleretinal screening. Ophthalmol Retin 2019; 3: 343-349 doi:10.1016/j.oret.2018.12.003
• 22 Framme C, Wolf-Schnurrbusch UEK, Lobsiger H. et al. Angepasstes und standardisiertes Patientenmanagement bei der Behandlung der neovaskulären AMD im ambulanten Bereich einer Universitäts-Augenklinik. Klin Monbl Augenheilkd 2012; 229: 812-821 doi:10.1055/s-0031-1299405
• 23 Ziemssen F, Spital G, Lemmen K. et al. Stellungnahme von DOG, Retinologische Gesellschaft und BVA: Therapie des diabetischen Makulaödems (2019). Accessed December 28, 2019 at: https://www.dog.org/wp-content/uploads/2013/03/Stellungnahme_DMP_2019_08-1.pdf
• 24 Schwarzer P, Ebneter A, Munk M. et al. One-year results of using a treat-and-extend regimen without a loading phase with anti-VEGF agents in patients with treatment-naive diabetic macular edema. Ophthalmologica 2019; 241: 220-225 doi:10.1159/000495623
• 25 Hufendiek K, Pielen A, Framme C. Injektionsstrategien bei der Anwendung intravitrealer VEGF-Inhibitoren: „Pro Re Nata versus Treat and Extend“. Klin Monbl Augenheilkd 2018; 235: 930-939 doi:10.1055/s-0042-122340
• 26 Volkmann I, Knoll K, Wiezorrek M. et al. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patientsʼ persistence. BMC Ophthalmol 2020; 20: 122 doi:10.1186/s12886-020-01397-x
• 27 Berufsverband der Augenärzte Deutschlands e.V. (BVA), Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG). Zentrale Aspekte zur Durchführung und Indikationsstellung der IVOM. Kurzstellungnahme von BVA, DOG und RG (2017). Accessed January 7, 2020 at: https://www.retinologie.org/fileadmin/Dateien/RG_Behandlungsempfehlungen/2017_Kurzstellungnahme_IVOM_BVA_DOG_RG.pdf
• 28 Deutsche Ophthalmologische Gesellschaft (DOG). Qualitätssicherung der optischen Kohärenztomografie für die Diagnostik des Augenhintergrunds. Stellungnahme von BVA, DOG und RG. Klin Monbl Augenheilkd 2017; 234: 1026-1033 doi:10.1055/s-0043-111075
• 29 Berufsverband der Augenärzte Deutschlands e.V. (BVA), Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG). Stellungnahme der Deutschen Ophthalmologischen Gesellschaft, der Retinologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands: Endophthalmitis-Prophylaxe bei intravitrealer operativer Medikamenteneingabe (IVOM). Stand September 2013. Accessed January 7, 2020 at: https://www.dog.org/wp-content/uploads/2013/03/Stand-Sep-2013-IVOM-topische-Antibiose.pdf
• 30 Greb O, Abou Moulig W, Hufendiek K. et al. [Software-based visualization of patient flow at a university eye clinic]. Ophthalmologe 2017; 114: 237-246 doi:10.1007/s00347-016-0316-7
• 31 Pauleikhoff D, Kirchhof B. Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of „lesion activity“. Graefes Arch Clin Exp Ophthalmol 2011; 249: 631-632 doi:10.1007/s00417-011-1639-3
• 32 Framme C, Panagakis G, Walter A. et al. Interobserver variability for retreatment indications after Ranibizumab loading doses in neovascular age-related macular degeneration. Acta Ophthalmol 2012; 90: 49-55 doi:10.1111/j.1755-3768.2010.01940.x